Information Provided By: 
Fly News Breaks for May 1, 2018
DGX
May 1, 2018 | 07:43 EDT
As reported previously, Baird analyst Eric Coldwell assumed Quest Diagnostics with an Outperform rating, up from the firm's prior Neutral coverage. The analyst noted lab growth is not overwhelming, but said with the environment moving more to a value and outcomes-based care and reimbursement model, labs provide more precise, valuable, and actionable data. Coldwell raised his estimates and his price target to $115 from $106 on Quest Diagnostics shares.
News For DGX From the Last 2 Days
DGX
Apr 25, 2024 | 05:10 EDT
DGX
Apr 24, 2024 | 09:46 EDT
DGX
Apr 24, 2024 | 09:10 EDT
DGX
Apr 24, 2024 | 06:55 EDT
UBS raised the firm's price target on Quest Diagnostics to $146 from $139 and keeps a Neutral rating on the shares. UBS is more confident that Quest can hit its margin expansion story following the Q2 print and the firm's call with management, the analyst tells investors in a research note. Labor cost trends seem to have already peaked and Covid revenues should no longer be a headwind starting 2H, while above market base volume growth continues, the firm notes.
DGX
Apr 24, 2024 | 06:43 EDT
DGX
Apr 24, 2024 | 06:24 EDT
Citi raised the firm's price target on Quest Diagnostics to $145 from $135 and keeps a Neutral rating on the shares post the Q1 report. The company increased the midpoint of its fiscal 2024 revenue target and management anticipates the rest of fiscal year to follow regular seasonality on a revenue and margin basis with a step-up into Q2, the analyst tells investors in a research note.
